Trial Profile
Effect of Subcutaneous Immunoglobulin (IgSC) Gammanorm® on the Distribution of IgG Subclasses and on the Humoral Immunity of Patients With Secondary Immunodeficiency.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- Sponsors Octapharma
- 25 Feb 2022 Status changed from recruiting to completed.
- 19 Dec 2017 New trial record